FibroBiologics, Inc. (FBLG) Stock Statistics & Valuation Metrics

FibroBiologics, Inc. has a market cap or net worth of $19.41M. The enterprise value is $25.97M.

FibroBiologics, Inc. has 75,089,930 shares outstanding. The number of shares has decreased by -2.65% in one year.

FibroBiologics, Inc.’s return on equity (ROE) is -4.08 and return on invested capital (ROIC) is -103.38%.

The current PE Ratio of FibroBiologics, Inc. is ―. FibroBiologics, Inc.’s PEG ratio is 0.14.

In the last 12 months, FibroBiologics, Inc. had revenue of 0.00 and earned -11.16M in profits. Earnings per share was -0.34.

In the last 12 months, operating cash flow was -16.30M and capital expenditures -361.00K, giving a free cash flow of -16.66M billion.

FibroBiologics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

FibroBiologics, Inc. upcoming earnings date is Apr 6, 2026, After Close (Confirmed).

FibroBiologics, Inc. as a current ratio of 1.12, with Debt / Equity ratio of 1253.02%

In the past 12 months, FibroBiologics, Inc. has paid 0.00 in taxes.

FibroBiologics, Inc. EV to EBITDA ratio is -4.54, with an EV/FCF ratio of -5.16.

FibroBiologics, Inc. has $4.87M in cash and marketable securities with $7.11M in debt, giving a net cash position of -$2.25M billion.

Gross margin is 12.82%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for FibroBiologics, Inc. is $3.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy